Research programme: inflammation therapy - AIM Therapeutics

Drug Profile

Research programme: inflammation therapy - AIM Therapeutics

Alternative Names: AIM 101; AIM 501; AIM-002; Ep1B; feG; Neutropel

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Alberta; University of Calgary; University of Western Ontario
  • Class Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Asthma; Cardiovascular disorders; Spinal cord injuries; Type 1 diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in Canada (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Canada (Parenteral)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Spinal-cord-injuries in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top